|
|
T7-alum |
|
Vaxjo ID |
308 |
|
Vaccine Adjuvant Name |
T7-alum |
|
Adjuvant VO ID |
VO_0005711
|
|
Description |
4C-Staph: multicomponent S. aureus candidate vaccine. T7-alum: novel TLR7-dependent adjuvant. |
|
Stage of Development |
Research |
|
Host Species for Testing |
Mouse |
|
Components |
TLR7 agonist adsorbed to alum |
|
Dosage |
One dose/single immunization |
|
Function |
Type: combination vaccine adjuvant. Target Receptor: Toll-like receptor 7 (TLR7). Induces Th1/Th17 mixed immune profile. one immunization with a multicomponent S. aureus candidate vaccine, 4C-Staph, formulated with a novel TLR7-dependent adjuvant, T7-alum, readily protected mice from death and from bacterial dissemination, both in kidney abscess and peritonitis models, outperforming alum-formulated vaccine. |
|
Safety |
N/A (study in mice focused on efficacy, no human safety data) |
| References |
Mancini et al., 2016: Mancini F, Monaci E, Lofano G, Torre A, Bacconi M, Tavarini S, Sammicheli C, Arcidiacono L, Galletti B, Laera D, Pallaoro M, Tuscano G, Fontana MR, Bensi G, Grandi G, Rossi-Paccani S, Nuti S, Rappuoli R, De Gregorio E, Bagnoli F, Soldaini E, Bertholet S. One Dose of Staphylococcus aureus 4C-Staph Vaccine Formulated with a Novel TLR7-Dependent Adjuvant Rapidly Protects Mice through Antibodies, Effector CD4+ T Cells, and IL-17A. PloS one. 2016; 11(1); e0147767. [PubMed: 26812180].
|
|
